Kaneez Leonard, MD
Family Medicine · Knoxville, TNNPI 1346451747
Payments from drug & device makers
Across 599 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Bayer$749
- Pfizer$720
- Otsuka America Pharmaceutical, Inc.$603
- plus $3K from 29 others
What the payments were for
- Food & beverage$9,898100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 134 | $1,911 |
| Lilly USA, LLC | 92 | $1,439 |
| Novo Nordisk | 92 | $1,429 |
| Bayer | 36 | $749 |
| Pfizer | 40 | $720 |
| Otsuka America Pharmaceutical, Inc. | 34 | $603 |
| Amgen(2 entities) | 33 | $524 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $334 |
| AstraZeneca | 16 | $318 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $308 |
| Axsome Therapeutics, Inc. | 16 | $264 |
| Boehringer Ingelheim | 11 | $164 |
| Exact Sciences | 7 | $133 |
| Astellas Pharma US Inc | 5 | $110 |
| Novartis | 7 | $99 |
| Medtronic | 3 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Merck | 4 | $72 |
| Organon | 1 | $71 |
| Lundbeck LLC | 4 | $68 |
| GSK | 4 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| Boston Scientific | 2 | $39 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Eisai Inc. | 2 | $25 |
| Abbott | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,917 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 110 | $158,661 |
| MounjaroTirzepatide | 93 | $112,724 |
| JardianceEmpagliflozin | 58 | $75,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $42,844 |
| EliquisApixaban | 26 | $29,669 |
| FarxigaDapagliflozin Propanediol | 29 | $28,444 |
| WegovySemaglutide | 19 | $24,503 |
| JanuviaSitagliptin Phosphate | 19 | $21,709 |
| VraylarCariprazine Hcl | 14 | $21,593 |
| Spiriva HandihalerTiotropium Bromide | 24 | $11,808 |
| XareltoRivaroxaban | 14 | $11,147 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $9,744 |
| Vilazodone Hcl | 23 | $3,837 |
| Omeprazole | 156 | $3,337 |
| Imipramine Pamoate | 12 | $3,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $1,429 | $183,164129 claims |
| Lilly USA, LLCMounjaro | $1,439 | $112,72493 claims |
| Boehringer IngelheimJardiance | $164 | $75,70258 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $65 | $52,58865 claims |
| AstraZenecaFarxiga, Symbicort | $318 | $31,51442 claims |
| PfizerEliquis | $720 | $29,66926 claims |
| AbbVieVraylar, Synthroid | $1,911 | $23,69841 claims |
| MerckJanuvia | $72 | $21,70919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Knoxville
- Rickey ManningKnoxville$8.1M
- Paul WakefieldKnoxville$4.3M
- Jerry PunchKnoxville$2.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Emily HubbsKingsport$2.8M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.